Biologic agents that neutralize specific cytokines like TNF-α or IL-6 have demonstrated efficacy in preclinical periodontitis models but carry the risk and cost associated with systemic immunosuppressive therapies (42). The gene discussed is TNF; the disease is periodontitis.